Zacks: Analysts Expect Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Will Post Quarterly Sales of $108.15 Million

Analysts expect that Eagle Pharmaceuticals, Inc. (NASDAQ:EGRXGet Rating) will announce $108.15 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Eagle Pharmaceuticals’ earnings, with estimates ranging from $107.50 million to $108.80 million. Eagle Pharmaceuticals posted sales of $48.12 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 124.8%. The business is expected to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Eagle Pharmaceuticals will report full-year sales of $398.80 million for the current financial year. For the next financial year, analysts anticipate that the company will post sales of $292.55 million, with estimates ranging from $265.20 million to $319.90 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Eagle Pharmaceuticals.

Eagle Pharmaceuticals (NASDAQ:EGRXGet Rating) last announced its quarterly earnings data on Monday, May 9th. The specialty pharmaceutical company reported $4.04 earnings per share for the quarter, beating the consensus estimate of $3.19 by $0.85. Eagle Pharmaceuticals had a return on equity of 18.56% and a net margin of 14.56%. During the same period in the previous year, the business posted ($0.03) earnings per share.

Several equities analysts have recently weighed in on the company. StockNews.com started coverage on Eagle Pharmaceuticals in a report on Thursday, March 31st. They issued a “buy” rating for the company. Zacks Investment Research upgraded shares of Eagle Pharmaceuticals from a “sell” rating to a “strong-buy” rating and set a $52.00 price target for the company in a research report on Wednesday, May 18th. One investment analyst has rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Eagle Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $51.50.

A number of hedge funds have recently added to or reduced their stakes in EGRX. Allspring Global Investments Holdings LLC acquired a new position in Eagle Pharmaceuticals in the fourth quarter valued at $14,018,000. Balyasny Asset Management LLC acquired a new position in Eagle Pharmaceuticals in the third quarter valued at $9,220,000. Goldman Sachs Group Inc. lifted its holdings in Eagle Pharmaceuticals by 65.3% in the first quarter. Goldman Sachs Group Inc. now owns 178,306 shares of the specialty pharmaceutical company’s stock valued at $8,825,000 after buying an additional 70,438 shares during the period. Two Seas Capital LP acquired a new position in Eagle Pharmaceuticals in the fourth quarter valued at $2,296,000. Finally, Krensavage Asset Management LLC lifted its holdings in Eagle Pharmaceuticals by 52.2% in the third quarter. Krensavage Asset Management LLC now owns 107,773 shares of the specialty pharmaceutical company’s stock valued at $6,012,000 after buying an additional 36,969 shares during the period. Institutional investors and hedge funds own 88.71% of the company’s stock.

Shares of NASDAQ EGRX opened at $46.94 on Friday. The stock has a market capitalization of $596.09 million, a price-to-earnings ratio of 16.95 and a beta of 0.68. The business has a 50-day moving average of $47.30 and a 200-day moving average of $48.36. Eagle Pharmaceuticals has a fifty-two week low of $36.48 and a fifty-two week high of $58.25.

About Eagle Pharmaceuticals (Get Rating)

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

Recommended Stories

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.